About AFSTYLA
Driven by Our Promise™
CSL Behring innovates and collaborates to improve access and care for patients.
About hemophilia A
Maintaining therapeutic factor trough levels between doses is critical to prevent bleeding in patients with hemophilia A.1
AFSTYLA offers long-lasting protection from bleeds, with clinical data demonstrating zero bleeds (median annualized spontaneous bleeding rate [AsBR],* n=226) on prophylaxis regimen regardless of age.2
AFSTYLA also offers 7 dosing strengths for optimal flexibility and efficiency, plus twice-weekly dosing available to meet your members’ needs.2†
Additionally, zero inhibitors were observed in a clinical trial of 258 previously treated patients. The formation of neutralizing antibodies (inhibitors) to factor VIII (FVIII) has been reported following administration of AFSTYLA. The most common adverse reactions reported in clinical trials (>0.5%) were dizziness and hypersensitivity.2
AFSTYLA twice weekly† is predicted to provide protection with FVIII median trough levels of 1.9%.3‡
Explore more clinical information here.
*AsBR in clinical trials (interquartile range [IQR]=0-2.4 patients aged ≥12 years; 0-2.2 for patients aged <12 years).
†US Food and Drug Administration (FDA) approved for 2x- to 3x-weekly dosing.
‡Median trough levels of simulated steady-state FVIII activity following doses of 50 IU/kg AFSTYLA in adolescents and adults.
What is AFSTYLA?
AFSTYLA, Antihemophilic Factor (Recombinant), Single Chain, is indicated in adults and children with hemophilia A (congenital factor VIII [FVIII] deficiency) for2:
treatment and control of bleeding episodes
Routine
prophylaxis to reduce frequency of bleeding episodes
Perioperative
management of bleeding
AFSTYLA is not indicated for the treatment of von Willebrand disease.
Please see full prescribing information for AFSTYLA.
What are the clinical benefits?
2x-weekly dosing4§
Zero bleeds
Median AsBR5-7||
§Protection delivered with a low number of factor units for both 2x- or 3x-weekly dosing regimens.
||Decreased risk of breakthrough bleeds associated with fewer hospital admissions and other positive outcomes.
What are the economic benefits?
AFSTYLA demonstrates significant economic benefits vs other long-acting recombinant FVIII (rFVIII) treatments, including8:
Comparable
Efficacy and dosing frequency
Up to 18% reduction in factor consumption
Lowest annual consumption¶
Up to 38% savings
Lowest yearly cost¶
- Decreased risk of breakthrough bleeds associated with fewer hospital admissions and other positive outcomes5-7
¶Based on results from a real-world patient chart study sourced from geographically diverse hemophilia treatment centers of AFSTYLA, Adynovate®, and Eloctate® (n=40 for each product). Data were gathered from May 2018 to July 2018, with data for some patients including 2+ years of treatment. Patients must have been treated prophylactically, on their current rFVIII treatment for 8 weeks or more, with an alignment of age and severity mix.
Want to learn more?
Meet with your CSL Behring Corporate Account Manager.
Help us help you
Share your thoughts so we can further tailor our content.